Cargando…
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells
Cladribine (2CdA), a synthetic purine analog interfering with DNA synthesis, is a medication used to treat hairy cell leukemia (HCL) and B-cell chronic lymphocytic leukemia. Entinostat, a selective class I histone deacetylase (HDAC) inhibitor, shows antitumor activity in various human cancers, inclu...
Autores principales: | Wang, Bolun, Lyu, Hui, Pei, Shanshan, Song, Deye, Ni, Jiangdong, Liu, Bolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197031/ https://www.ncbi.nlm.nih.gov/pubmed/29969371 http://dx.doi.org/10.1080/15384101.2018.1464849 |
Ejemplares similares
-
Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023) -
Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma
por: Ma, Jian, et al.
Publicado: (2011) -
Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma
por: Koerber, Ruth-Miriam, et al.
Publicado: (2015) -
Revisiting entinostat as an immune-potentiating adjuvant
por: McCaw, Tyler R., et al.
Publicado: (2018) -
Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)